Tom Beer

Dr. Tomasz (Tom) Beer is a Professor of Medicine and Grover C. Bagby Endowed Chair for Prostate Cancer Research in the Division of Hematology & Medical Oncology, where he leads the Prostate Cancer Research Program, encompassing basic research, translational research, clinical trials of novel therapeutic strategies in prostate cancer, and studies aimed at enhancing cancer survivorship. He has authored or co-authored more than 25 peer reviewed articles on prostate cancer. Dr. Beer is particularly known for investigations of targeted therapies and immunotherapies in prostate cancer, including vitamin D receptor, the androgen receptor, and clustering targeting agents as well as cancer vaccines, CTLA-4 and PD-1 inhibitors, and others. He led the global randomized trial of enzalutamide vs placebo which demonstrated substantial improvements in overall and progression-free survival as well as quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer. Dr. Beer serves as Deputy Director of the OHSU Knight Cancer institute, and NCI designated Comprehensive Cancer Center. He also serves as Chief Medical Officer for the Center for Early Detection Advanced Research (CEDAR) within the Knight where he works closely with a diverse leadership team to speed advances in the early detection of lethal cancers. At CEDAR, Dr. Beer fosters collaborations between clinicians, engineers, and cancer biologists to advance discoveries in early detection of cancer and leads clinical trials of multi-omic blood based cancer early detection tests. Dr. Beer cares for men with prostate cancer at OHSU and at the Portland VA Medical Center.

Disclosures: Tom serves as a consultant to GRAIL and is involved in the ongoing Pathfinder study.